Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs)

Wang, Qiong; Chen, Sihui; Wang, Junhui; Shang, Huifang; Chen, Xueping

doi:10.3390/brainsci14100990

Open AccessEditor’s ChoiceReview

Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs)

by

Qiong Wang

^1,†,

Sihui Chen

^2,†,

Junhui Wang

^3,4

,

Huifang Shang

² and

Xueping Chen

^2,*

¹

Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

²

Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China

³

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada

⁴

Thyropathy Hospital, Sunsimiao Hospital, Beijing University of Chinese Medicine, Tongchuan 727000, China

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Brain Sci. 2024, 14(10), 990; https://doi.org/10.3390/brainsci14100990

Submission received: 2 September 2024 / Revised: 26 September 2024 / Accepted: 27 September 2024 / Published: 29 September 2024

(This article belongs to the Section Neuropharmacology and Neuropathology)

Download

Browse Figure

Versions Notes

Abstract

The landscape of pharmacological treatment for Alzheimer’s disease (AD) has undergone significant transformations with the advent of disease-modifying therapies (DMTs) targeting β-Amyloid (Aβ) accumulation, one of the hallmark pathologies of AD. The approval and market introduction of monoclonal antibodies mark the dawn of a new era in AD therapeutics as well. Furthermore, considerable progress has also been made in the development of new drugs targeting non-Aβ and non-Tau protein pathways. These advancements are key in tackling the root causes of AD, offering hope for treatments that both relieve symptoms and slow disease progression, improving patient outcomes and quality of life. This review aims to provide a comprehensive update on the advances in drug development and application for AD, including those currently in clinical trials and those already approved for the market to treat patients.

Keywords: Alzheimer’s disease; disease-modifying therapies (DMTs); monoclonal antibodies; therapy

Share and Cite

MDPI and ACS Style

Wang, Q.; Chen, S.; Wang, J.; Shang, H.; Chen, X. Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs). Brain Sci. 2024, 14, 990. https://doi.org/10.3390/brainsci14100990

AMA Style

Wang Q, Chen S, Wang J, Shang H, Chen X. Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs). Brain Sciences. 2024; 14(10):990. https://doi.org/10.3390/brainsci14100990

Chicago/Turabian Style

Wang, Qiong, Sihui Chen, Junhui Wang, Huifang Shang, and Xueping Chen. 2024. "Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs)" Brain Sciences 14, no. 10: 990. https://doi.org/10.3390/brainsci14100990

APA Style

Wang, Q., Chen, S., Wang, J., Shang, H., & Chen, X. (2024). Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs). Brain Sciences, 14(10), 990. https://doi.org/10.3390/brainsci14100990

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs)

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI